報價延遲最少15分鐘:2024/11/10 13:05 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.17 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.19/-0.13
|
|
企業價值
729.82M
|
| 資產負債 |
|
每股賬面淨值
3.26
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
169.02M
|
|
每股收益
3.22
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/10 13:05 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States. |